top of page

NSW Sector News - August 2023


  1. Vivax Pharma raises $20 million to develop new treatments for malaria. Vivax Pharma, a Sydney-based biotech company, has raised $20 million in Series A funding to develop new treatments for malaria. The company's lead drug candidate, VPX-102, is a novel antimalarial compound that is currently in Phase 1 clinical trials. The funding will be used to advance VPX-102 through clinical trials and to develop other new treatments for malaria.

  2. Immunocore receives FDA approval for Phase 2 trial of cancer vaccine. Immunocore, a Sydney-based biotech company, has received FDA approval to begin a Phase 2 trial of its cancer vaccine, IMP761. The vaccine is designed to target a protein called PD-1, which is found on the surface of cancer cells. The FDA approval is a major milestone for Immunocore and will help the company to advance IMP761 towards commercialization.

  3. Endomag raises $25 million to develop new cancer imaging technology. Endomag, a Sydney-based medical device company, has raised $25 million in Series B funding to develop its new cancer imaging technology. The technology uses magnetic resonance imaging (MRI) to detect and track cancer cells. The funding will be used to further develop the technology and to conduct clinical trials.

  4. Neurala Therapeutics secures $20 million to develop new brain implants for Parkinson's disease. Neurala Therapeutics, a Sydney-based biotech company, has secured $20 million in Series A funding to develop new brain implants for Parkinson's disease. The implants are designed to deliver electrical stimulation to the brain to improve symptoms of the disease. The funding will be used to develop the implants and to conduct clinical trials.

  5. Acacia Stem Cells secures $5 million to develop new stem cell treatments for spinal cord injuries. Acacia Stem Cells, a Sydney-based biotech company, has secured $5 million in seed funding to develop new stem cell treatments for spinal cord injuries. The company's lead drug candidate, ASC-001, is a stem cell-based therapy that is currently in preclinical studies. The funding will be used to advance ASC-001 through preclinical studies and to prepare for clinical trials.

  6. Cytosyn Pharma partners with CSIRO to develop new cancer drugs. Cytosyn Pharma, a Sydney-based biotech company, has partnered with CSIRO, Australia's national science agency, to develop new cancer drugs. The partnership will focus on using CSIRO's expertise in synthetic biology to develop new cancer targets and drugs. The partnership is expected to accelerate the development of new cancer treatments.

  7. Stem Cell Australia receives $5 million grant to develop stem cell therapies for diabetes. Stem Cell Australia, a Sydney-based research institute, has received a $5 million grant from the Australian government to develop stem cell therapies for diabetes. The institute is working on a number of projects, including developing stem cells that can produce insulin and transplanting stem cells into the pancreas. The grant will help the institute to accelerate its research and to bring new stem cell therapies to patients with diabetes.

  8. OncoStem completes Phase 1 clinical trial of cancer stem cell treatment. OncoStem, a Sydney-based biotech company, has completed a Phase 1 clinical trial of its cancer stem cell treatment, ONX-01. The trial was a success and showed that ONX-01 was safe and well-tolerated. The company is now planning to conduct a Phase 2 clinical trial of ONX-01.

  9. Vivax Pharma announces new partnership with Monash University. Vivax Pharma, a Sydney-based biotech company, has announced a new partnership with Monash University. The partnership will focus on developing new treatments for malaria. Monash University is a leading research university in Australia with expertise in malaria research. The partnership is expected to accelerate the

Comments


bottom of page